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Abstract 
Subcutaneous (SC) injection is currently the most common route of self-administering 
biopharmaceuticals such as proteins and peptides. While pharmaceutical scientists have acquired 
great skill in identifying formulations for these as proteins and peptides with multi-year shelf life 
stability, the SC injection of these formulations can result in inconsistent or particularly low 
bioavailability outcomes. We hypothesise that upon injection, the chemical, physical and 
physiological properties of the subcutaneous tissue may play a crucial role in determining the 
therapeutic outcomes of SC injected biopharmaceuticals. We contend that physical and chemical 
stresses placed upon the injected protein or peptide as is transitions from the non-physiological 
environment of its formulation to the homeostatic conditions of the SC tissue can affect its fate 
following injection. In this mini-review we describe how events that occur to an injected protein or 
peptide during this post-injection transition period could affect the diffusion of bioactive material to 
blood capillaries and lymphatic vessels.  With this in mind, we have reviewed the chemical, physical 
and physiological attributes of the SC tissue and collated studies on how these properties are known 
to affect protein stability and diffusional properties. Finally, examples where the understanding of 
the properties of the SC tissue when formulating for SC injected biopharmaceuticals has improved 
the predictability of drug delivery via the SC route are discussed, with the need for novel tools for 
rational and informed formulation development is highlighted.   
Keywords: Biopharmaceuticals, subcutaneous injection, formulation 
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Introduction – subcutaneous tissue and variability of delivered biopharmaceuticals 
The subcutaneous (SC) injection site is positioned below the dermis where it functions in energy 
storage and hydration as well as a thermal insulator and shock absorber to protect underlying 
musculoskeletal structures [1]. SC tissue is composed of two different tissue types; loose connective 
tissue, also known as areolar tissue, and underneath that, adipose tissue [2]. Blood capillaries to 
sustain the viability and nerve fibres with various types of endings to provide the skin with its critical 
sensory function permeate the SC tissue [3]. A lymphatic capillary bed resides within the SC space 
and there is very little proteolytic activity in the subcutaneous tissue [3]. These features make SC 
tissue an ideal route for administering biopharmaceuticals that are not suitable for oral delivery due 
to proteolytic degradation within and/or limited absorption across the epithelial barrier of the 
gastrointestinal tract.  The SC route, however, introduces other uncertainties in drug delivery, such 
as variable bioavailability between different formulations and various injection sites of the body [4].   
Patients are not administered drugs, they are administered formulations that contain a drug and 
subcutaneously injected biopharmaceuticals are often formulated in non-physiological conditions 
that function to improve shelf-life stability [5, 6]. Indeed, biopharmaceuticals intended for SC 
injection are commonly formulated at acidic pH with a variety of stabilizing agents [6, 7]. One can 
assume that upon administration the SC injection site returns to homeostasis condition of the body, 
with the temporal parameters of this recovery being dependent upon injection volume and 
formulation composition.  We hypothesize that this period of transition from the formulation 
environment to the homeostatic environment of the SC tissue can be detrimental for some 
biopharmaceuticals, in particular proteins and some peptides. Such detrimental changes to proteins 
and peptides injected into the SC space, due to alterations in their structural properties could 
adversely affect their functional properties. Further, we hypothesize that these changes could alter 
the ability for an injected biopharmaceutical to be absorbed efficiently from the SC injection site.  
Our hypotheses related to the potential for a period of possible instability during the transition from 
environmental conditions of an injected formulation to the homeostatic condition of the body 
provides a potential explanation for the observation that some proteins and peptides injected into 
the SC space have bioavailability outcomes that are unacceptably low or variable.  In that light, the 
current review article aims to summarise the chemical, physical and physiological characteristics of 
the subcutaneous tissue, highlighting the need for considering not only shelf-life stability but also 
the properties of the subcutaneous tissue in the optimization of protein and peptide formulations 
intended for SC injection. A second aspect of the review aims to illustrate how characteristics of the 
SC injection site may affect pharmacokinetic and/or pharmacodynamic profiles of 
biopharmaceuticals following SC injection. Finally, the future perspectives of SC drug delivery, 
formulation improvements and emerging analytical techniques for enhancing the efficacy of SC drug 
delivery are highlighted in the last part of the review article. It is important to note that this mini-
review focuses on events occurring shortly after the injection; longer term adverse effects, such as 
immunogenicity that may or may not be a result of the potential post-injection stability issues [8] is 
outside the remit of the current review.   
Physiological, physical and chemical properties of the subcutaneous injection site  
The major physiological and chemical features of the subcutaneous tissue are schematically 
presented in Figure 1. These are the extracellular matrix formed by collagen, hyaluronic acid and 
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chondroitin sulfate, the interstitial fluid, the temperature of the tissue and hydrostatic and osmotic 
pressure.  From this diagram, it can be appreciated that the SC injection site contains an organization 
of collagen proteins that provides a lattice network to support integrated elements of 
polysaccharides. These are discussed in detail in the following section.    
 
 
Figure 1. Diagram describing the organization of non-viable elements within the subcutaneous 
injection site.  Stands represent network of collagen fibrils. Hexagons represent glycosaminoglycan 
components such as hyaluronic acid (HA) and chondroitin sulphate.  For simplicity, only HA is 
represented with its single carboxylic acid group. Physiologically relevant ions as well as the pH and 
approximate temperature of this tissue are noted.   
 
Extracellular matrix  
When the extracellular matrix (ECM) was first discovered, it was described as “an amorphous ground 
substance” [9]. However, as the understanding of the functional properties of the ECM organisation 
improved it became obvious that it is a highly ordered structure with collagen providing mechanical 
stability in form of a three dimensional network, and glycosaminoglycans, most commonly 
hyaluronic acid and chondroitin sulphate, filling the void spaces within the collagen network [10]. 
Specific elements of the ECM will be discussed in detail in the following sections of the paper.   
Collagen 
Collagen is the most abundant protein within the body of mammals and forms fibrous structures 
that function as structural elements in the ECM, tendons and basement membranes [11]. There are 
several types of collagen undertaking different functions in the body that can be grouped according 
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to the function they have in the body: fibril forming collagens (I, II, III, V and XI), fibril associated 
collagens (IX, XII and XIV), microfibrillar collagen (VI), short chain collagens (X and VIII) and basement 
membrane collagen (IV) [12]. The most prevalent collagens in loose connective tissue, such as that 
present in the SC injection site, are types I and III [13].  
A generalized collagen structure is illustrated in Figure 2. The common primary amino acid sequence 
for all collagen types is a repeating (glycine-X-Y) motif, where X and Y can be any amino acid but are 
frequently proline (Pro) or hydroxyproline (Hyp) residues [14]. The collagen polypeptide forms a left-
handed helix with the glycine (Gly) residues positioned on the same axis throughout the helix. The 
imino acid residues of Pro and Hyp sterically stabilise the secondary structure known as α-chain, and 
three α-chains form a triple helical, closely packed, supercoiled collagen fibril structure with the Gly 
residues packed inside the triple helix [15], as illustrated in Figure 2. The Hyp residues also 
participate in stabilising the collagen fibril structure in aqueous solution by enabling water bridge 
formation between its hydroxyl groups located in adjacent α-chains [14, 16]. The diameter of a 
typical collagen fibril is approximately 1.4 nm and length approximately 300 nm [17].   
Collagen fibrils in the ECM are associated in bundles via interactions mediated by proteoglycans, 
forming collagen fibres that are between 1 and 100 µm thick. The fibrils taking part in a bundle can 
branch and the branched bundle in turn can take part in fibre formation elsewhere, thus creating a 
branched collagen network [18].  When observed with microscopic techniques, D-periodicity that is 
a structure where neighbouring fibres are displaced from each other axially with a distance of D due 
to electrostatic and hydrophobic interactions between the adjacent fibrils,  is characteristic of 
collagen [12], as illustrated in Figure 2.  The isoelectric point of type I collagen has been reported as 
approximately 10 [19], meaning that at physiological pH, collagen carries a net positive charge; the 
net charge of collagen at physiological pH and ionic strength has been measured as +14 mV [20]. 
Collagen concentration in the subcutaneous tissue has been reported to be 55% of dry weight in rat 
subcutaneous tissue [21], and 50% of dry weight in normal human skin [22]. To the authors’ best 
knowledge, the collagen concentration in the subcutaneous tissue of man has not been reported in 
the literature.   
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Figure 2. A schematic of collagen fibre assemblies in subcutaneous tissue. A) Organization of amino 
acids in the repeating collagen α-chain sequence and left handed helical structure assembly with 
glycine (Gly) residues stacking on the same axis and X and Y (most commonly proline and 
hydroxyproline) forming the outside edge of the chain. B) Organization of three α-chains assembled 
into a collagen fibril with Gly residues of adjacent chains packing into the center of the helix fiber to 
expose and X and Y residues at the outer surface. C) Assembly of fibrils into a D-periodic collagen 
fibre.  
 
Hyaluronic acid 
Hyaluronic acid (HA), also known as hyaluronan or hyaluronate, is a mucopolysaccharide that fills in 
the void spaces within the collagen fibre network, as illustrated in Figure 1. The chemical structure of 
HA is shown in Figure 3. The basic building block of this biopolymer is a disaccharide unit formed of 
N-acetyl-D-glucosamine (GlcNAc) and D-glucuronic acid (GlcA) linked together via a β1-4 glycosidic 
bond.  These disaccharides are, in turn, joined by β1-3 bonds to form a linear (unbranched) 
polysaccharide that can have a molecular weight of up to 2000 kilodaltons (kDa) [23-25]. HA is also 
capable of forming ordered tertiary structures, such as double helixes [26].  
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Figure 3. Chemical structure of hyaluronic acid. The repeating disaccharide unit is composed of N-
acetyl-D-glucosamine (GlcNAc) and D-glucuronic acid (GlcA) that are linked by a β1-4 glycosidic 
bond.  These disaccharides are joined together by β1-3 bonds to form a linear, unbranched 
polysaccharide. At physiological pH, the carbonate groups of GlcA carry a negative charge.  
In addition to the large molecular weight of the molecule, another remarkable feature of HA is that 
at physiological pH and ionic strength, the carboxylic acid groups of GlcA molecules predominantly 
carry a negative charge [23].  The polyanionic nature and large molecular weight of the molecule 
contribute to the function of HA within the body in providing matrix structures, maintaining water 
balance of the body, regulating the distribution of proteins in the tissues by steric exclusion and, due 
to its unique rheological properties, lubricating joints and tissues [24]. 
The concentration of hyaluronic acid in the subcutaneous tissue is approximately 1 gram in 100 
grams of wet tissue [27]. HA is degraded within the body and the relatively rapid half-life of HA in 
the tissues varies between half a day and three days. Degraded HA components are taken up by the 
lymphatic system [25]. 
Chondroitin sulfate 
The chemical structure of chondroitin sulfate (CS), a linear glycosaminoglycan polysaccharide that is 
composed of repeating disaccharide units of D-glucuronic acid (GlcA) and D-galactosamine (GalN), is 
shown in Figure 4. The D-galactosamine units are sulfated either at C-4 or C-6 positions of the 
polysaccharide chain producing either chondroitin-4-sulfate or chondroitin-6-sulfate, respectively. 
The molecular weight of CS in tissues is often between 30 and 40 kDa [28]. Similar to HA, CS is also 
negatively charged at a physiological pH. However, the charge density of CS is twice as high as that 
of HA due to the fact that both GlcA and GalN residues are anionic in a CS molecule while HA carries 
a single negative charge per disaccharide unit [29].   
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Figure 4. Chemical structure of chondroitin sulfate (CS). The repeating disaccharide unit of CS is 
composed of D-glucuronic acid (GlcA) and D-galactosamine (GalN). Possible sulfation positions in the 
D-galactosamine unit (C-4 or C-6) are illustrated.  
 
It has been suggested that CS may act as a viscosity modifier within the ECM, as it has been shown 
that the viscosity of chondroitin sulfate solutions on their own is very low, while the addition of CS 
into HA solution increases the viscosity of the HA [30].  It has also been suggested that CS 
participates in water uptake and nutrient absorption within the tissues [28]. There is a paucity of 
information on the CS concentration in subcutaneous tissue. However, SC tissue is classified as loose 
connective tissue, and the ratio of HA to CS in Wharton’s Jelly, another tissue classified as loose 
connective tissue, has been reported as approximately 2 in 1 [31].  
Interstitial fluid 
The subcutaneous space is perfused with the interstitial fluid, the body fluid that is not held within 
cells or in blood plasma, and that accounts for approximately 25% of total body water in man [32].  
The pH of interstitial fluid is maintained at approximately pH 7.4 [33].  Factors that contribute to the 
pH regulation of the interstitial fluid are the dissociation constant of water, the strong ion difference 
([SID]) and the partial pressure of carbon dioxide in the tissue, while also fulfilling the principle of 
electrostatic neutrality [34]. As illustrated by Table I, the main cation dissolved in the interstitial fluid 
is sodium with minor amounts of potassium, magnesium and calcium also present. The main non-
volatile anion is chloride with a minor proportion of sulphate. Notably, phosphate has been omitted 
from the table as its concentration in extracellular body fluids is negligible [34].  
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Table I. The concentrations of different anions and cations in the interstitial fluid. Adapted from [34].  
Cation Concentration (Eq/l) Anion Concentration (Eq/l) 
Na+ 0.137 Cl- 0.111 
K+ 0.003 HCO3
- 0.031 
Mg2+ 0.002 SO4
2- 0.001 
Ca2+ 0.001 CO3
2- 0.000045 
    
Total cations 0.143 Total anions 0.143 
 
The concentration of sodium ions is higher than the concentration of chloride ions, thus resulting to 
a positive strong ion difference [SID] of the interstitial fluid. As a result, without dissolved carbon 
dioxide (CO2), the pH of the extracellular fluid would be approximately 11.9 [33]. However, at 
positive [SID], the presence of gaseous carbon dioxide, which is a product of cell metabolism, 
decreases the pH of the solution due to the favoured formation of bicarbonate (HCO3
-) and 
carbonate (CO3
2-) ions to neutralise the positive [SID].  Consequentially, the interstitial fluid pH in a 
closed system is only regulated by the [SID] and the partial pressure of CO2; addition of H
+ ions into 
this closed system does not significantly change the pH [34].   
Within the SC tissue, the interstitial fluid is not a closed system but is in an equilibrium with the 
intracellular fluid and blood plasma compartments [34]. Following cell metabolism, CO2 and weak 
acids, such as lactate, will be excreted from the cells into the interstitial fluid. The increase in CO2 
does not alter the pH of the interstitial fluid as CO2 is rapidly diffused into the plasma and dealt with 
by the respiratory system. However, the increase in weak acids, such as lactate, will increase the 
[SID] and consequentially decrease the pH. The decrease in pH is counteracted by exchanging other 
strong ions between the cellular and interstitial compartments to neutralise the [SID] and thus a 
physiological pH is restored [34]. In the balance of all of these interacting factors, the interstitial fluid 
bicarbonate concentration is maintained at approximately 25 mM [35]. 
Pressure 
SC tissue interstitial pressure is primarily regulated by two factors: the interstitial fluid hydrostatic 
pressure PIF caused by the limited volume of the sc space and the colloid osmotic pressure PCO 
exerted by plasma proteins through the semipermeable capillary wall. PIF and PCO, in conjunction 
with lymphatic flow, control the volume of the interstitial fluid, and thus the pressure, in the tissues 
[36, 37]. SC tissue values of PIF have been reported as slightly negative at –1 to -2 mmHg [37, 38] and 
the elastic nature of the dermis allows for changes in water content of the SC space to occur while 
maintaining the PIF within a normal physiological range [39]. Positive values of PIF, however, are 
associated with different pathological conditions, such as oedema [38], as such events result in fluid 
accumulation that exceeds the elastic properties of the overlying dermis and underlying 
musculoskeletal structures. Thus, changes in the PIF value are normally connected to changes in the 
fluid volume within the SC tissue; increased interstitial fluid volume can result in an increase of PIF 
[36].  
PCO is, in essence, the difference between colloid osmotic pressures of plasma and interstitial fluid 
[37]. The colloid osmotic component (PCO) has been reported as 15.8 mmHg in the subcutaneous 
tissue of thorax [40] and 10.2 mmHg in the SC tissue of the ankle [41] in man. PCO may be altered in 
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some pathological conditions where plasma protein leakage through the capillaries occurs, i.e. pre-
eclampsia [42].  
Temperature 
Temperature of the human body is generally regarded as approximately 37°C.  However, this is the 
temperature of the body’s core and temperature of the SC tissue at comfortable environmental 
temperature (~20°C) have been shown to average approximately 34°C [43, 44]. Sites closer to the 
body’s core, such as chest and back, demonstrate slightly higher temperatures than the extremities 
such as thighs, calves, feet and arms [44].  Importantly, one of the roles of the SC tissue is systemic 
thermal regulation. Consequentially, SC tissue temperature has been shown to average 30°C on the 
onset of shivering and 36°C on the onset of sweating [44]. In this way, SC tissue temperatures are 
typically maintained within a range of 30-36°C. 
 
Potential stressors experienced by a biopharmaceutical upon transition from the formulation 
environment to the environment of the SC injection site 
Extracellular matrix binding interactions  
To be absorbed into the systemic circulation in a biologically active form, a biopharmaceutical must 
remain sufficiently stable following its SC injection prior to uptake into blood capillaries and 
lymphatic vessels. Depending on the glycosaminoglycan concentration of SC tissue and molecular 
weight of the solute, molecules within the SC tissue can be transported either by diffusional or by 
convective flow [27].  ECM components of the SC injection site, however, can pose a resistance to 
the solute flow. As highlighted in the previous section, the ECM is composed of a collagen network 
with void spaces filled with HA and CS. These components determine the tissue’s resistance to flow 
via a complex interplay; it has been shown in experimental studies with model ECMs that the 
resistance of SC tissue to flow is lower than that of a model collagen network or of a model HA 
matrix at physiologically relevant concentrations [45]. Combining the effect of HA and collagen was 
still found to underestimate the flow resistance of the tissue, and theoretical models have shown 
that the presence of proteoglycans, such as CS, add significant flow resistance in the tissues [45].   
Steric exclusion 
Steric exclusion of a biopharmaceutical entity may be one of the mechanisms influencing the rate of 
drug and excipient transport, and thus absorption, from the SC injection site.  For example, 
hyaluronic acid has been shown to act as a molecular sieve and thus affect diffusion rates of proteins 
through HA solutions, with both increasing concentration of HA and increasing size of a globular 
molecule transported through the matrix resulting in a decreased diffusion rate [46]. Steric exclusion 
has also been attributed to account for the differences observed in diffusion rates of 
macromolecules of different shapes through HA with elongated particles shown to diffuse faster 
than globular particles of similar molecular weight [47].  
Steric exclusion by HA may also affect protein solubility at the SC injection site. It has been shown 
that when added in a solution of HA, steric exclusion of proteins takes place and consequentially, the 
solubility of proteins is decreased with larger proteins being more affected than smaller ones [47, 
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48].  This effect is dependent on the HA concentration with higher concentrations producing lower 
protein solubilities [49].  Therefore, it may be that, due to their larger size (up to 150 kDa) and 
generally high concentration formulations (up to 150mg/ml) [6], monoclonal antibodies (mAbs) 
injected into SC tissue may be especially susceptible to precipitation via the mechanism of steric 
exclusion.  
Electrostatic interactions 
Electrostatic interactions have also been suggested to play a role in regulating macromolecular 
diffusion through HA matrices. Diffusional rates of different macromolecules in HA and HA-collagen 
matrixes are dependent on the HA concentration with increasing HA concentration posing more 
hindrance on diffusion both in the presence and absence of collagen [50]. In the presence of 
collagen, however, the extent of hindrance to diffusion posed by the HA was found to be reduced 
compared to aqueous solutions of HA at equivalent concentrations. This was explained by 
neutralisation of some of the negative charges of HA due to interactions with the positive charges on 
collagen [50].  
Electrostatic interactions may also influence the stability of injected biopharmaceutical. Indeed, a 
theoretical study indicated that proteins form electrostatically stabilised complexes with 
polyelectrolytes and that the formation of these complexes is mainly regulated by the surface charge 
of the proteins [51]. Experimental work proved that complex formation between a polyelectrolyte 
and a protein may take place even close to the isoelectric point (pI) of the protein where the net 
charge is essentially zero but regional charged patches would still exist [52, 53].  In a separate study 
it was found that positively charged therapeutic antibodies bound to homogenised rat SC tissue in a 
way that was dependent of both pH and the ionic strength, indicating that electrostatic interactions 
were playing a role in determining the extent of absorption of these antibodies from the SC injection 
site [54]. The relationship between the pharmacokinetic (PK) and pharmacodynamic (PD) properties 
of intravenously administered mAb formulations and protein charge have also been investigated, 
and it was concluded that after extravasation, electrostatic ECM-protein interactions played a part in 
determining PK/PD properties [55, 56]. 
It is clear that the transport of molecules though the ECM is a complex phenomenon and regulated 
by a variety of mechanisms, such as steric exclusion and electrostatic interactions. A computational 
study indicated that there is a complex interplay between the interactions and the diffusing entities; 
for particles that were significantly smaller than the ECM pore structure, electrostatic effects 
appeared to be the most significant determinant of diffusion rates as neutral particles were seen to 
diffuse more rapidly than cationic particles. For nanoparticles with size similar to the pore size of the 
ECM, steric hindrance became significant and the charge of the particles was negligible in 
determining the diffusion rate [57]. Consequentially, in biopharmaceutical formulations, the rate 
and the mechanism regulating the transport rate of the active ingredient (API) may be completely 
different compared to those observed for stabilising excipients present in the formulation.  
Specific versus non-specific interactions 
It has been suggested that one of the functions of the extracellular matrix is to store biologically 
active molecules, such as growth factors, so that they are readily available when adjacent cells 
require them [58]. Therefore, it is not surprising that one of the factors affecting uptake of a 
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biopharmaceutical from the SC injection site may be its binding to ECM components. For example, 
HA has both non-specific and specific interactions with proteins, with the specific interactions being 
ascribed to certain HA functions within the body and the non-specific interactions due to the 
polyelectrolyte nature of HA [59]. Specific HA binding partners are most commonly found in cartilage 
where HA plays a role in stabilising the structure [60], or on cell surfaces where interactions between 
cells and the ECM are mediated via receptors such as CD44 [61].  
Proteins involved in these interactions, called hyaladherins, bind HA; hyaladherins contain a linking 
module that is a structural domain composed approximately of 100 amino acids enriched in basic 
amino acids, such as arginine, which may bind HA via electrostatic interactions [62]. However, some 
proteins lacking this linking module still bind HA [62], and several studies have shown that proteins 
lacking specific HA binding domains, such as bovine serum albumin (BSA) [63, 64] and lysozyme [65] 
can form complexes with HA. In case of BSA it was shown that at physiological ionic strengths, 
insoluble neutral complexes and charged, soluble complexes between BSA and HA could form that 
were dependent upon stoichiometry; at excess HA concentrations, soluble, negatively charged, 
unfolded ribbon complexes of large size are formed. If the stoichiometry of HA and BSA resulted in 
neutral complexes, these tended to aggregate to larger precipitates due to the lack of electrostatic 
repulsion. At excess BSA concentrations, positively charged, soluble compact complexes were 
formed [64].   
These studies clearly demonstrate that there is a potential of some biopharmaceuticals forming non-
specific complexes with HA that may be relevant to their successful SC administration. However, in 
addition to binding HA, biopharmaceutical binding to collagen and CS may also take place, thus 
altering the therapeutic outcomes after SC injection. For example, a study by Yaoi, Hashimoto, 
Takahara and Kato [66] reported that insulin had a high binding affinity to collagen, especially to 
type V, although it was also found to bind to other collagens (e.g. types I, II and IV).  Interleukin-8 (IL-
8), a naturally occurring chemokine administered via SC injection to reduce inflammation, has been 
shown to bind to CS in the lungs via an interaction mediated by its glycosaminoglycan binding 
domain consisting mainly of basic amino acids. This binding was suggested to act as a mediator of 
the local concentration of IL-8 and the subsequent duration of action for IL-8 in the lungs in 
regulating inflammation [67].   
Excipient-API interactions  
A variety of excipients, including sugars, salts, and surfactants are used for each biopharmaceutical 
to achieve a multi-year shelf life required for commercial success (Figure 5A). It is conceivable that 
API-excipient interactions may also factor into determining the PK and PD outcomes following the SC 
injection of a biopharmaceutical formulation. These effects would be due to potential alterations in 
API-excipient interactions following the injection of a biopharmaceutical formulation into SC tissue. 
The primary basis for such potential effects are related to pH-dependent events associated with the 
transition from acidic  (4-6) pH conditions frequently used to stabilize a biopharmaceutical to the 
neutral pH of the body following SC injection. Several potential scenarios for pH-dependent changes 
in API-excipient have been illustrated in Figure 5. The nature of these API-excipient changes could be 
due to charge and/or conformation differences of the biopharmaceutical induced by a transition 
from acidic to neutral pH. Importantly, this pH change can result in a swing through the pI for many 
protein and peptide therapeutics; a situation where proteins can be poorly soluble and prone to 
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detrimental aggregation [68]. The loss of the protective actions of some of the excipients could be 
problematic and in the other hand, their local concentration, such as that of a surfactant, could have 
damaging actions on the biopharmaceutical. 
One potential scenario involving API-excipient interactions that could positively affect the fate of a 
biopharmaceutical following its SC injection involves retention of these interactions during the 
transition through potentially stressful environmental changes (Figure 5B). It is easy to envisage that 
the low molecular weight excipients would rapidly leave the SC injection site, potentially leaving the 
high molecular weight API at risk of deleterious associations with itself (aggregation) or with ECM 
components (Figure 5C). One could envision pH-dependent changes in chemical and/or physical 
properties of the API that might alter their affinity for some of the formulation excipients that might 
result in positive or negative outcomes (Figure 5D). Finally, It is possible that environmental changes 
occurring during the transition from the injected formation to the homeostatic conditions of the SC 
tissue could modify the properties of some excipient, potentially producing an environment where 
the API might be more or less stable (Figure 5E). Thus, interactions between an API and its 
excipients, between individual API molecules, or an API and ECM elements could be occurring that 
might affect the nature of the API at the SC injection site. Indeed, pH-dependent changes in physical 
properties of the API and/or the stabilizing excipient would be a likely cause for these potential 
changes in associations.  
Excipient-ECM interactions  
In an ideal situation, the interactions prevailing in the formulation are maintained within the SC 
tissue environment and the protein remains stable and available to be transported for absorption.  
In a non-optimal situation, the affinity of the excipients to the protein within the environment of the 
SC tissue may be diminished. While many of the mechanisms used by excipients to stabilize a 
biopharmaceutical in a vial can be considered generic in nature, events occurring at the SC injection 
site, however, could be unique for different biopharmaceuticals. For example, some excipients act as 
molecular crowders in the bulk solution to prevent protein aggregation in a formulation (Figure 5A; 
diamonds). Typically, after injection, water is removed from the SC injection site to maintain stable 
PIF and PCO. This leads to an increase in the local concentration of the biotherapeutic entity and the 
formulation excipients (Figure 5B).  Typically, small molecular weight excipients would leave the SC 
injection site more rapidly than the API. If the API is not affected by this or the residence time of the 
critical excipient at the injection site is sufficiently long, the API could be protected during the period 
of environmental stress (Figure 5C).  If there is an insufficient level of the critical excipient during the 
period of environmental stress, the injected API could have extensive interactions with ECM 
components or itself to result in deleterious aggregation events (Figure 5D). For example, if the 
critical excipient is a surfactant that functions to minimize protein-protein interactions to block 
aggregation, rapid loss of this material from the SC injection site could lead to a similar detrimental 
aggregation outcome.  
It is possible that some physical and/or chemical changes in the API during the period of transition 
from the stable formulation to SC tissue conditions alter the API-excipient interactions (Figure 5E). 
One could envisage how such changes could have either positive or negative outcomes for an API.    
Alternately, environmental changes could cause an excipient to display a higher affinity for ECM 
components than to the injected protein therapeutic, causing local high concentration of an 
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excipient and reducing the API-excipient interaction (Figure 5F). In the case where there is an 
increased avidity for the surfactant after the formulation is injected SC, local concentration of the 
surfactant could elevate above the critical micelle concentration, put the API at risk of detergent-
mediated denaturation. As another example, collagen molecules do not interact with sucrose but do 
bind divalent Ca2+ ions [20]. Chondroitin sulfate is known to bind Ca2+ and other divalent cations [69]. 
Thus, the ECM could rapidly extract divalent cations from an injected formulation under the certain 
conditions. It is also know that albumin binds fatty acids [70]. Therefore, some classes of surfactants 
present in the formulation may be preferentially bound by albumin within the SC space, leaving the 
therapeutic protein exposed to the SC tissue environment without the stabilising effect of the 
excipient.  However, it may also possible that at least one of the excipients will have a high affinity 
interaction with the ECM components, thus eliminating any unwanted ECM-API interactions, whilst 
the protein remains stable within the SC tissue. In this case, the protein diffusion to the capillaries 
and the lymphatics for systemic absorption could be enhanced.  
Ionic composition 
Dissolved anions and cations have the ability to alter water structure to different extent. Hofmeister 
was the first researcher to report the effect and consequentially, the rank order of different cations 
and anions in precipitating proteins out of solution is called the Hofmeister series. His original work 
is translated from German in reference [71]. According to the Hofmeister series, different ions have 
an ability to stabilise or destabilise proteins in aqueous solutions depending on the ions’ capability to 
disturb the hydrogen bonding network of water surrounding the protein [72]. This is because the 
protein is surrounded by three layers of water:  the solvation layer, the transition layer and the bulk 
layer. In essence, the solvation layer and the bulk water are competing of hydrogen bonding with 
the transition layer. If an added ion strengthens the hydrogen bonding network of the bulk water, 
the transition layer will participate in hydrogen bond formation with the bulk water. This decreases 
the solvent action on the protein surface and consequentially, the protein conformation is stabilised. 
In contrast, if the ion destabilises the hydrogen bonding network of the bulk water layer, the 
transition layer will participate in hydrogen bond formation with the solvation layer. This 
strengthens the solvent action on the protein surface, potentially leading to unfolding [72].  
Not surprisingly, the physiologically most important buffer, carbonate ion, has been reported as one 
of the most effective anions in stabilising bulk water, and thus protein, structure [72-74]. However, 
protein charge will also play a role in determining the impact of ions on the protein stability, and 
negatively charged proteins tend to follow the Hofmeister series while positively charged proteins 
frequently follow an inverse Hofmeister series [72]. Therefore, for a positively charged protein the 
presence of carbonate ions may have an adverse impact on conformational stability. This is 
particularly important as the pH of the SC space is stabilized by carbonate-based buffered system. 
Additionally, due to the fact that proteins exhibit both positive and negative charge patches on their 
surfaces, the Hofmeister effect may not always be straightforward [75], making the potential impact 
of the pH transition stress from a formulation to neutral pH in the SC injection site unique for each 
biopharmaceutical.    
Despite the complexities related to non-uniform surface charge of proteins, we anticipate that in 
some cases the Hofmeister series may be relevant for sc delivery of biopharmaceuticals due to what 
is essentially a buffer exchange upon injection from the formulation buffer to the SC tissue 
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physiological carbonate based buffer system. The protein may not be stable in the new buffer 
conditions, or the properties, such as the electrostatic characteristics, of the protein may change, 
and consequentially the transport of the protein through the ECM into the blood capillaries and the 
lymphatics for absorption may be altered.  For example, the results of a study by Cugia et al. [75] 
illustrate the significance of the buffer composition in determining the properties of the protein. In 
their study, the electrostatic motility of lysozyme was measured at constant pH of 7.15 in different 
buffer systems. The results were shown to be altered depending on the buffering system with 
phosphate and citrate producing vastly different results compared to a carbonate buffer [75].  
 
Figure 5. A schematic of potential active pharmaceutical ingredient (API)-excipient interaction 
outcomes following subcutaneous (SC) injection. A) Organization of components in the formulation 
during shelf storage depicting different degrees of API-excipient interactions. B) Upon injection into 
the SC tissue, to maintain stable PIF and PCO, water is removed from the injection site by the 
lymphatic system. This results to the formulation components concentrating at the injection site. 
Following this, multiple scenarios of protein and excipient fate are possible, as shown in the 
depiction of API- API-excipient interactions following removal of water from the SC injection site in a 
situation C) where pH transition does not strikingly affect these interactions, D) where transition to 
SC environment results in a rapid loss of all excipient protection with the outcome of self-
aggregation and/or strong interactions with SC tissue components, E) where transition to SC tissue 
environment results in an exchange of excipient affinities with the API and F) where the physical and 
possibly functional properties of an excipient are altered following transition to SC tissue 
environment.  The potential for different chemical and physical properties of the API between 
conditions in the starting formulation and the environment of the SC injection site is depicted by a 
transition in shading (lighter blue in the vial).  For a colour version of the schematic, the reader is 
referred to the electronic version of the mini-review. 
  
Tissue pH 
The pH of biopharmaceutical formulations is frequently within the range from 4 to 7 [76] whereas 
the pH within the subcutaneous tissue is approximately 7.4 [33]. It has been reported that due to the 
charged nature of its components, the extracellular matrix may act as a buffer upon addition of H+ 
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and OH- ions into the SC tissue [39]. Therefore, it is likely that the protein in the formulation will 
experience a rapid shift from the formulation pH to the physiological pH of the subcutaneous tissue. 
We hypothesise that in some cases, the protein stability may be compromised as a result of this 
shift.  In fact, the pH shift from the formulation pH to the sc tissue pH has been also successfully 
utilised as a method for controlled release of insulin glargine by formulating the insulin with a pI of 
6.7 at pH 4 [77]. Upon injection, the pH will shift through the isoelectric point of the protein causing 
the protein to precipitate in the presence of zinc ions.  With time, the precipitated insulin slowly 
becomes soluble again and therefore is gradually released from the injection depot. 
However, as discussed previously in this review, [SID] is the main determinant of the pH within the 
interstitial fluid of subcutaneous tissue. Strong ions in the interstitial fluid are Na+, K+, Ca2+, Mg2+ and 
Cl− , although also organic anions that are fully dissociated in the physiological pH, such as lactate, 
are strong ions [78]. Therefore, it may be possible that the pH of the injection site does not 
drastically change upon injection, unless the formulation contains strong ions as buffering agents. 
This is supported by a study where it was reported that the pain the patients experienced  upon 
injection was more serious for citrate than for histidine or saline [79]. This may be because citrate is 
a strong ion whereas histidine and saline are not. Therefore it may be possible that the pH shift 
within the SC tissue upon the administration of was more significant with citrate than with saline 
and histidine, resulting to a more painful injection.  
Tissue temperature 
To improve the stability of subcutaneously administered biopharmaceuticals, the long term storage 
of the formulations in a refrigerator is often recommended. Patients are instructed to remove a vial 
from the refrigerator before usage so that the temperature of the formulation reaches the ambient 
temperature prior to administration. However, despite the instructions, in some cases the 
formulation may experience a temperature change of approximately up to 30 °C upon 
administration into the SC tissue. In some cases the temperature change may prove to be sufficient 
to cause loss of activity. One protein with such properties is recombinant human granulocyte 
stimulating factor (rhGCSF) that has been shown to rapidly form dimers at 37°C. However, the dimer 
formation could be inhibited by adding sucrose into the formulation to act as a thermal protectant 
[80].  
Hydrostatic and oncotic pressure within the tissue 
The interstitial fluid hydrostatic pressure PIF is determined by two factors; the volume of interstitial 
fluid and the elasticity of the extracellular matrix [39].  Of these two factors, with the normal 
injection volumes of sc injected biotherapeutics being up to 1.5 ml for monoclonal antibodies [6], 
the volume of the interstitial fluid can definitely be expected to change upon injection. As a 
consequence, an increase in PIF is expected upon injection, and it has indeed been acknowledged 
that SC injection volumes of 2 ml produce pressure changes that are perceived as painful [2].  
Another factor regulating the PIF, the elasticity of the extracellular matrix, has been reported to be 
governed by electrostatic interactions [39]. In some cases, upon injection of a biopharmaceutical 
formulation, components of the formulation may neutralise some of the charges of the ECM, and 
consequentially alter the elasticity of the ECM, resulting to variations in the local PIF within the tissue 
upon injection of a formulation. Also, the colloid osmotic pressure (PCO) will change as a result of a 
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subcutaneous injection, as the concentration of solutes impermeable to the capillaries within the 
subcutaneous space is increased.  
As discussed earlier in the article, under normal circumstances the PIF within the subcutaneous tissue 
is slightly negative compared to the atmospheric pressure. Under these conditions, most of the 
interstitial fluid is bound within the extracellular matrix. However, when positive pressures are 
applied, the interstitial fluid becomes more mobile. This is because to maintain stable PIF, the 
lymphatic flow is increased [36, 81].  The changes in the PCO will also stimulate the lymphatic flow to 
reach a new equilibrium between the plasma and interstitial compartments [82]. Mechanisms that 
reduce plasma volume and interstitial fluid volume by increasing the lymphatic filtration, have been 
reported to have maintained relatively stable PCO values in patients with a variety of complications 
associated with diabetes [82]. Thus, SC tissue interstitial pressure is maintained within a fairly 
narrow range, even in the context of pathological conditions. Therefore, the SC injection of a 
formulation would likely result in only a transient change interstitial pressure driven by an increase 
in fluid volume and materials (a biopharmaceutical and excipients of a formulation) that affect the 
oncotic equilibrium. In the context of discussing the pressure changes within the SC tissue upon 
injection, it is interesting, however, that moderate pressures have been shown to affect the stability 
of some proteins; an effect that is pH dependent with maximal stability being observed at the pI 
[83]. Therefore, is some cases the pressure changes possibly taking place upon injection may have an 
impact on the protein stability.  
 
Future perspectives 
This review article has highlighted the importance of understanding the chemical, physical and 
physiological properties of the subcutaneous injection site, and how they may affect protein 
absorption and stability post SC administration. Understanding the significance of different 
interactions that may possibly take place between formulation components and SC tissue elements 
upon injection could enable tailoring of protein formulations to provide optimal stability not only for 
shelf-life but also upon SC administration. The likelihood of an injected biopharmaceutical reaching 
the blood capillaries and the lymphatic vessels for systemic absorption could also be improved by 
intelligent and informed formulations that consider diffusional barriers posed by the SC tissue; an 
example of a successful formulation approach that takes SC injection site chemistry into account is 
the addition of hyaluronidase, an enzyme that degrades the β-D-glucuronic bond in the HA 
molecule, into biopharmaceutical formulations. In nature, the enzyme is secreted for example as a 
part of snake venoms [84] and bacterial toxins [85] to aid their spread in the victim. This enzyme has 
been added to biopharmaceutical formulations to enable increasing injection volumes and to 
enhance biopharmaceutical transport through interstitial spaces as a result of the breakage of the 
diffusional barrier posed by HA, consequentially improving their bioavailability [86, 87]. Another 
successful approach in utilising the properties of the SC tissue to alter absorption and diffusion 
characteristics of a biopharmaceuticals is the fatty acid binding properties of albumin. In this regard, 
an insulin analogue has been developed to have an increased interaction with albumin, which results 
in decreased diffusion rate from the SC injection site to the systemic circulation and increased 
plasma half-life [88, 89].  
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One factor that has possibly limited the adoption of new formulation approaches for SC injected 
biotherapeutics that reflects the issues discussed in this review is that at present, there are no in 
vitro laboratory models available for predicting stability outcomes or for simulating the extent of 
these potential events following SC injection.  Formulation testing is currently performed in animals, 
but these are limited in their predictive capabilities of biopharmaceutical drug stability and extent of 
absorption in man upon injection, possibly due to anatomical and physiological differences between 
species [90]. Therefore, there currently remains a need to discover and develop in vitro methods 
that would accurately model the physiological, chemical and physical properties of the subcutaneous 
tissue and allow predicting the stability outcomes of subcutaneously injected biopharmaceutical 
formulations.  
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